Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3852788 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL4911781 | 0.89 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL4911776 | 0.89 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL3851207 | 0.85 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3851702 | 0.85 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3852603 | 0.81 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3922331 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3919389 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3918221 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3922338 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306116-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7579349-B2 | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1678169-B1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2008117051-A1 | S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008117051-A1 | S-6-METH0XY-2- (2- (3- (PYRIMID-2-YL) IS0XAZ0L-5-YL) PYRROLIDIN-1-YL) -4- (5-METHYL-IH-PYRAZOL-S-YLAMINO) PYRIMIDINE AND POLYMORPHIC FORMS THEREOF AS MODULATORS OF THE INSULIN-LIKE GROWTH | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | ASRAZENECA (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1931662-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | AstraZeneca AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1871771-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007031745-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| WO-2006109026-A1 | 4-(PYRID-2-YL) AMINO SUBSTITUTED PYRIMIDINE AS PROTEIN KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-19 | — | — | WO | disclosed |
| EP-1678169-A1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171742-A1 | 4-(Pyrid-2-Yl) Amino Substituted Pyrimidine as Protein Kinase Inhibitors | IGF1R, IGFBP1, IRS1 | CHRNB2 4564/4885CHRNA4 4629/4885CHRM5 4799/4885 |
| US-20080269266-A1 | NOVEL COMPOUNDS 747 | UGT2B7, UGT1A7, CYP3A7 | CHRNB2 4396/4885CHRNA4 4037/4885CHRM5 3938/4885 |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | CHRNB2 3865/4885CHRNA4 3879/4885CHRM5 3751/4885 |
| US-20090306116-A1 | PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF IGF-IR TYROSINE KINASE ACTIVITY | IGF1R, IGFBP1, IRS1 | CHRNB2 4477/4885CHRNA4 4553/4885CHRM5 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.